Pain response to palliative intent conventional radiotherapy for painful malignant iliopsoas involvement: a multicenter retrospective study [0.03%]
姑息放射治疗对骨盆恶性肿瘤髂腰肌受累患者止痛效果的多中心回顾性研究
Kenji Makita,Yojiro Ishikawa,Yuki Wada et al.
Kenji Makita et al.
Background: Evidence regarding the efficacy of palliative-intent conventional radiotherapy (conv-pRT) for painful malignant iliopsoas involvement (PMII), including malignant psoas syndrome (MPS)-related pain, caused by no...
Madoka Kisoi,Kotaro Yamashita,Kenji Kinoshita et al.
Madoka Kisoi et al.
Background: Cell-free DNA (cfDNA) analysis is an important tool in molecular diagnostics and translational research. However, conventional cfDNA extraction from plasma is often labor-intensive, and inefficient due to inte...
Japanese clinical practice guidelines for pharmacotherapy in older adults with cancer (second edition): an overview [0.03%]
日本老年癌症患者药物治疗临床实践指南（第二版）概要
Ayumu Matsuoka,Fumio Nagashima,Asao Ogawa et al.
Ayumu Matsuoka et al.
Background: The global population is aging rapidly, and the number of older adults with cancer is increasing worldwide. However, evidence supporting optimal pharmacotherapy for this population remains limited because olde...
RNF125 mediates the anti-breast cancer activity of betulinic acid through ubiquitin-dependent degradation of MYH9 [0.03%]
乌本苷酸通过泛素依赖的MYH9降解抑制乳腺癌中RNF125的作用机制研究
Peng Zhang,Yuan Chang,Xiaolu Yang et al.
Peng Zhang et al.
Background: Breast cancer (BC) represents one of the leading causes of cancer-related mortality in women worldwide. Betulinic acid (BA), a naturally derived pentacyclic triterpenoid, exhibits anti-BC activity. Recent evid...
Ocular toxicities associated with anticancer drug therapy in Asian patients: a literature review and practical management recommendations for non-ophthalmologic settings [0.03%]
抗肿瘤药物治疗相关的亚洲患者眼部毒性反应：文献回顾及非眼科临床环境下的管理建议
Yohei Limura,Hitomi Sakai,Isana Nakajima et al.
Yohei Limura et al.
Background: Ocular toxicities associated with anticancer therapies, including cytotoxic chemotherapy, hormonal agents, molecular targeted therapies, immune checkpoint inhibitors, and antibody-drug conjugates, are increasi...
The role of surgical timing in survival of patients with spinal metastases [0.03%]
脊柱转移性疾病患者手术时机对生存率的影响分析
Miklós Kopa,Ádám Kővári,Lukács Németh et al.
Miklós Kopa et al.
Background: Spinal metastases commonly cause pain, neurological deterioration, and instability. Surgery is palliative, aiming to relieve symptoms and maintain oncologic treatment eligibility. Optimal surgical timing, howe...
Event-free survival and recurrence patterns after curative resection for locally advanced head and neck squamous cell carcinoma: single-institution real-world outcomes prior to the introduction of perioperative immunotherapy [0.03%]
术前免疫治疗时代之前局部晚期头颈部鳞癌根治性手术的无事件生存和复发模式：单中心真实世界结果分析
Takuma Makino,Yuto Naoi,Go Hasegawa et al.
Takuma Makino et al.
Background: Perioperative immune checkpoint inhibitors have improved outcomes for resectable locally advanced head and neck squamous cell carcinoma (HNSCC). However, real-world surgical outcome data based on contemporary ...
Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial [0.03%]
皮下注射mosunetuzumab联合polatuzumab vedotin治疗复发/难治性大B细胞淋巴瘤的疗效和安全性：SUNMO三期临床试验日本亚组分析
Dai Maruyama,Hideki Goto,Takahiro Kumode et al.
Dai Maruyama et al.
Background: Novel, accessible treatment options, are needed for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Mosunetuzumab, a T-cell-engaging bispecific antibody, plus polatuzumab vedotin, an anti...
Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers [0.03%]
针对晚期肿瘤的分子谱系指导疗法KOSMOS I，II研究：EGFR扩增转移性实体瘤使用厄洛替尼加贝伐单抗治疗的结果
Jiwon Lee,Jongmin Sim,Yun-Gyoo Lee et al.
Jiwon Lee et al.
Purpose: Epidermal growth factor receptor (EGFR) amplification remains a controversial therapeutic biomarker. We report outcomes of erlotinib plus bevacizumab (E + B) in patients with EGFR-amplified metastatic solid tumor...
Treatment strategies and outcomes in patients with synchronous multiple primary malignancies involving lung cancer [0.03%]
同步多原发癌（伴肺癌）的治疗策略及预后分析
Ryu Kanzaki,Hisaya Chikaraishi,Takuya Tokunaga et al.
Ryu Kanzaki et al.
Background: Synchronous multiple primary malignancies (sMPMs) involving lung cancer present complex clinical challenges requiring individualized treatment strategies. While surgical outcomes have been reported, data on lo...